Spots Global Cancer Trial Database for etrumadenant
Every month we try and update this database with for etrumadenant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | NCT03846310 | Non Small Cell ... Non Small Cell ... Nonsquamous Non... Sensitizing EGF... | Etrumadenant Zimberelimab Carboplatin Pemetrexed Pembrolizumab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies | NCT03720678 | GastroEsophagea... Colorectal Canc... | etrumadenant mFOLFOX | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma | NCT06048484 | Pancreatic Duct... | Stereotactic bo... Zimberelimab Quemliclustat Etrumadenant Modified FOLFIR... | 18 Years - | Columbia University | |
| A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma | NCT05886634 | Dedifferentiate... Soft Tissue Sar... Sarcoma,Soft Ti... Sarcoma Recurrent Dedif... Unresectable De... Metastatic Dedi... | Etrumadenant Zimberelimab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer | NCT04262856 | Non Small Cell ... Nonsquamous Non... Squamous Non Sm... Lung Cancer | Domvanalimab Etrumadenant Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | NCT03821246 | Prostate Adenoc... Prostate Cancer Localized Prost... | Atezolizumab Tocilizumab Etrumadenant | 18 Years - | University of California, San Francisco | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer | NCT04791839 | Non Small Cell ... Non-small Cell ... Non-small Cell ... | Zimberelimab Domvanalimab Etrumadenant | 18 Years - | Washington University School of Medicine | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy | NCT03821246 | Prostate Adenoc... Prostate Cancer Localized Prost... | Atezolizumab Tocilizumab Etrumadenant | 18 Years - | University of California, San Francisco | |
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | NCT05915442 | Oligometastatic... | Quemliclustat Etrumadenant Zimberelimab Stereotactic Bo... | 18 Years - 99 Years | Columbia University | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | NCT03719326 | TNBC - Triple-N... Ovarian Cancer | Etrumadenant IPI-549 Pegylated lipos... nanoparticle al... | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer | NCT05177770 | Metastatic Cast... Prostate Cancer | SRF617 etrumadenant zimberelimab | 18 Years - | Coherus Biosciences, Inc. | |
| A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | NCT05411146 | Healthy Partici... | [14C]-etrumaden... | 18 Years - 55 Years | Arcus Biosciences, Inc. | |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | NCT05335941 | Urothelial Carc... Metastatic Canc... | Pemetrexed Zimberelimab Etrumadenant | 18 Years - | M.D. Anderson Cancer Center | |
| A Study Investigating the Safety, Absorption, and Elimination of Radioactively Labeled Etrumadenant, a New Compound in the Treatment of Cancer | NCT05411146 | Healthy Partici... | [14C]-etrumaden... | 18 Years - 55 Years | Arcus Biosciences, Inc. | |
| A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies | NCT03629756 | Non-small Cell ... Squamous Cell C... Breast Cancer Colorectal Canc... Melanoma Bladder Cancer Ovarian Cancer Endometrial Can... Merkel Cell Car... GastroEsophagea... Renal Cell Carc... Castration-resi... | Etrumadenant Zimberelimab | 18 Years - | Arcus Biosciences, Inc. | |
| A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers | NCT04892875 | Head and Neck C... Squamous Cell C... Oral Cavity Squ... Oral Cavity Can... Oropharynx Canc... Oropharynx Squa... Larynx Cancer Pharynx Cancer Hypopharynx Can... Hypopharynx Squ... | Zimberelimab Etrumadenant Cisplatin Radiation | 18 Years - | Vanderbilt-Ingram Cancer Center | |
| A Phase 2 Study to Evaluate the Triplet Combination of Pemetrexed Plus AB928 (Etrumadenant) + AB122 (Zimberelimab) in Patients With Previously Treated Advanced or Metastatic MTAP Deficient Urothelial Carcinoma | NCT05335941 | Urothelial Carc... Metastatic Canc... | Pemetrexed Zimberelimab Etrumadenant | 18 Years - | M.D. Anderson Cancer Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
